This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy

Testing for BRAF V600 variants in tumor tissue of patients with unresectable or metastatic melanoma may be considered medically necessary to select patients for treatment with Food and Drug Administration-approved BRAF inhibitors, MEK inhibitors, or immunotherapy.Testing for BRAF V600 variants in tumor tissue of patients with resected stage III melanoma may be considered medically necessary to select patients for treatment with Food and Drug Administration-approved BRAF or MEK inhibitors.

Testing for BRAF V600 variants for all other patients with melanoma is considered investigational.

Testing for BRAF V600 variants in patients with glioma to select patients for targeted treatment is considered investigational.

Testing for tumor mutational burden (TMB) in patients with unresectable or metastatic melanoma or glioma to select patients for treatment with Food and Drug Administration-approved immunotherapy is considered investigational.

787-277-6653 787-474-6326